Literature DB >> 7758564

Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993.

T Schaberg1, G Gloger, B Reichert, H Mauch, H Lode.   

Abstract

Resistance of Mycobacterium tuberculosis (M.tb) strains is an increasing problem worldwide. Since no public health data are available for urban populations in Germany, we investigated resistance in our hospitalized patients (n = 1,011) over the last 7 yrs. We therefore evaluated clinical data and results of susceptibility tests (breakpoint technique/proportion method) for isoniazid, streptomycin, rifampin, pyrazinamide, protionamide and ethambutol. Since 1987, there has been a relatively constant rate of 5.9% (3.9%-7.8%) for single-drug resistance (SDR), but an increasing rate of multidrug-resistant (MDR) strains (> or = 2 first-line drugs) from 1.7% in 1987 to 5.8% in 1993. Sixty nine percent of patients with MDR strains showed resistance to two drugs, and 31% to three or more drugs. Risk factors for SDR and MDR tuberculosis revealed previous therapy (odds ratio (OR) (95% confidence interval (95% CI)); SDR 2.2 (1.7-4.0); MDR 4.5 (2.3-8.8)); and foreign-born status (SDR 2.2 (1.3-3.6); MDR 3.5 (1.8-6.8)) to be the most important factors associated with resistance. Both primary and acquired resistance were higher in foreign-born than in German-born patients. We conclude that there was a considerable increase in multidrug-resistant tuberculosis in our hospital from 1987 to 1993. Since previously treated patients and patients born in countries with a high level of primary resistance had an increased risk of drug-resistant tuberculosis, we would advise a four drug regimen as initial therapy in those patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7758564     DOI: 10.1183/09031936.95.08020278

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Survey of drug-resistant tuberculosis in northwestern Russia from 1984 through 1994.

Authors:  M K Viljanen; B I Vyshnevskiy; T F Otten; E Vyshnevskaya; M Marjamäki; H Soini; P J Laippala; A V Vasilyef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

Review 2.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review.

Authors:  A Faustini; A J Hall; C A Perucci
Journal:  Thorax       Date:  2005-10-27       Impact factor: 9.139

3.  Ciprofloxacin once daily versus twice daily for the treatment of pulmonary tuberculosis.

Authors:  H Bergstermann; A Rüchardt
Journal:  Infection       Date:  1997 Jul-Aug       Impact factor: 3.553

4.  Risk factors for multidrug-resistant tuberculosis: A worldwide systematic review and meta-analysis.

Authors:  Ying Xi; Wei Zhang; Rui-Jun Qiao; Jun Tang
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 5.  Tuberculosis and HIV infection: a review.

Authors:  D Schürmann; S D Nightingale; F Bergmann; B Ruf
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 7.455

6.  Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea.

Authors:  J H Lee; J H Chang
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.